The post hoc use of randomised controlled trials to explore drug associated cancer outcomes: Methodological challenges

Current Drug Safety

Volumn 8, Issue 5, 2013, Pages 371-378

  Stefansdottir, Gudrun ^a,b   Zoungas, Sophia ^c,d   Chalmers, John ^c   Knol, Miriam J ^a,b   Leufkens, Hubert G M ^b   Woodward, Mark ^c   Patel, Anushka ^c   Grobbee, Diederick E ^a   De Bruin, Marie L ^a,b  

^a UMCU   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF SYDNEY   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

ADVANCE; Cancer; Insulin; Methodological issues; Post hoc analysis; Power

Indexed keywords

HEMOGLOBIN A1C;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RISK; CASE CONTROL STUDY; DRUG INDUCED CANCER; DRUG USE; FOLLOW UP; HUMAN; INSULIN TREATMENT; PANCREAS CANCER; PHARMACOEPIDEMIOLOGY; POST HOC ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 84891498078     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/15748863113086660070     Document Type: Article

References (37)

1. Hoover R, Fraumeni JR J. Drugs in Clinical Use Which Cause Cancer. J Clin Pharmacol 1975; 15(1): 16-23.
2. Hoover R, Fraumeni JRJ. Drug-Induced Cancer. Cancer 1981; 47(1): 1071-80.
3. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of Antidiabetic Agents and the Risk of Pancreatic Cancer: A Case-Control Analysis. Am J Gastroenterol 2012; 107(4): 620-6.
4. Beiderbeck-Noll AB, Sturkenboom MC, van der Linden PD, et al. Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study. Eur J Cancer 2003; 39(1): 98-105.
5. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9(7): 695-9.
6. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 2012; 11: 409.
7. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pop s09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
8. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004; 64(24): 9209-16.
9. Wang V, Li C, Lin M, et al. Ovarian cancer is a heterogeneous disease. Cancer Genet Cytogenet 2005; 161(2): 170-3.
10. Zhang Y, Zhu C, Curado MP, Zheng T, Boyle P. Changing patterns of bladder cancer in the USA: evidence of heterogeneous disease. BJU Int 2012; 109(1): 52-6.
11. Study rationale and design of ADVANCE: action in diabetes and vascular disease-preterax and diamicron MR controlled evaluation. Diabetologia 2001; 44(9): 1118-20.
12. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2560-72.
13. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829-40.
14. Grobbee DE, Hoes AW. Clinical Epidemiology: principles, methods and applications for clinical research. 1 ed. Sudbury, MA: Jones and Bartlett Publishers, LLC; 2008. p. 413.
15. Lu CY. Observational studies: a review of study designs, challenges and strategies to reduce confounding. Int J Clin Pract 2009; 63(5): 691-7.
16. Navarro C, Chirlaque MD, Tormo MJ, et al. Validity of self reported diagnoses of cancer in a major Spanish prospective cohort study. J Epidemiol Community Health 2006; 60(7): 593-9.
17. Desai MM, Bruce ML, Desai RA, Druss BG. Validity of selfreported cancer history: a comparison of health interview data and cancer registry records. Am J Epidemiol 2001; 153(3): 299-306.
18. Stavrou E, Vajdic CM, Loxton D, Pearson SA. The validity of selfreported cancer diagnoses and factors associated with accurate reporting in a cohort of older Australian women. Cancer Epidemiol 2010; 35(6): e75-80.
19. ICH Topic E 6 (R1) Guideline for Good Clinical Practice. Note for Guidance on Good Clinical Practice. July 2002 (CPMP/ICH/ 135/95). 2002.
20. Glaziou P. Sampsize Calculator. Available online at: http://sampsiz e.sourceforge.net/. 2005.
21. Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 2009; 16(2): 429-41.
22. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009; 16(4): 1103-23.
23. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28(1): 20-47.
24. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006; 23(6): 579-93.
25. Adami HO, McLaughlin J, Ekbom A, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991; 2(5): 307-14.
26. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159(12): 1160-7.
27. Godsland IF. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (Lond) 2009; 118(5): 315-32.
28. Zhou XH, Qiao Q, Zethelius B, et al. Diabetes, prediabetes and cancer mortality. Diabetologia 2010; 53(9): 1867-76.
29. Smith U, Gale EA. Cancer and diabetes: are we ready for prime time? Diabetologia 2010; 53(8): 1541-4.
30. Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC. Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings-what, why and how? Diabetes Obes & Metab 2012; 14(7): 579-85.
31. Grzeskowiak LE, Gilbert AL, Morrison JL. Investigating outcomes associated with medication use during pregnancy: A review of methodological challenges and observational study designs. Reprod Toxicol 2012; 33(3): 280-9.
32. Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health 2000; 21: 121-45.
33. Tamim H, Monfared AA, LeLorier J. Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf 2007; 16(3): 250-8.
34. Horwitz RI, Feinstein AR. The problem of "protopathic bias" in case-control studies. Am J Med 1980; 68(2): 255-8.
35. Yang X, Ko GT, So WY, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes 2010; 59(5): 1254-60.
36. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011; 54(1): 25-31.
37. Stefansdottir G, Zoungas S, Chalmers J, et al. Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia 2011; 54(7): 1608-14.